Daily Endocrinology Research Analysis
Three impactful endocrinology-related studies emerged: a Science paper reveals a gut–joint axis where intestinal FXR signaling modulates osteoarthritis via GLP-1, a Diabetes Care study shows that adding selected proteomic biomarkers significantly improves 10-year type 2 diabetes risk prediction beyond clinical scores, and a double-blind RCT in JCEM finds no short-term neurodevelopmental benefit of testosterone during minipuberty in infants with 47,XXY despite clear anabolic effects and HPG-axis
Summary
Three impactful endocrinology-related studies emerged: a Science paper reveals a gut–joint axis where intestinal FXR signaling modulates osteoarthritis via GLP-1, a Diabetes Care study shows that adding selected proteomic biomarkers significantly improves 10-year type 2 diabetes risk prediction beyond clinical scores, and a double-blind RCT in JCEM finds no short-term neurodevelopmental benefit of testosterone during minipuberty in infants with 47,XXY despite clear anabolic effects and HPG-axis suppression.
Research Themes
- Microbiome–hormone cross-talk (GLP-1) and osteoarthritis pathophysiology
- Proteomics-enhanced precision risk prediction for type 2 diabetes
- Pediatric endocrine therapeutics: testosterone during minipuberty in 47,XXY
Selected Articles
1. Osteoarthritis treatment via the GLP-1-mediated gut-joint axis targets intestinal FXR signaling.
This study defines a gut–joint axis in which decreased GUDCA and intestinal FXR signaling modulate osteoarthritis via GLP-1. In mice, inhibiting intestinal FXR alleviated osteoarthritis through GLP-1, and GLP-1 receptor activation mitigated disease while blockade attenuated benefits. Human cohorts showed altered bile acid metabolism consistent with the mechanism.
Impact: It uncovers a mechanistic link between intestinal FXR, GLP-1 signaling, and osteoarthritis, suggesting repurposing GLP-1 receptor agonists and targeting gut bile acid pathways for joint disease.
Clinical Implications: GLP-1 receptor agonists may offer disease-modifying potential in osteoarthritis; modulation of intestinal FXR or bile acid composition could become therapeutic targets pending clinical trials.
Key Findings
- Osteoarthritis cohorts showed reduced glycoursodeoxycholic acid (GUDCA) and altered microbial bile acid metabolism.
- Suppressing intestinal FXR alleviated osteoarthritis in mice via intestine-secreted GLP-1.
- GLP-1 receptor activation mitigated osteoarthritis, whereas GLP-1 receptor blockade attenuated benefits.
Methodological Strengths
- Integration of two independent human cohorts with mechanistic mouse experiments.
- Pharmacological receptor modulation (FXR and GLP-1R) to test causality.
Limitations
- Human data are observational and do not establish clinical efficacy of interventions.
- Translational generalizability from mice to human osteoarthritis remains to be proven.
Future Directions: Conduct randomized clinical trials of GLP-1 receptor agonists in osteoarthritis; test intestinal FXR modulators and bile acid interventions; define microbiome drivers of GUDCA changes.
Whether a gut-joint axis exists to regulate osteoarthritis is unknown. In two independent cohorts, we identified altered microbial bile acid metabolism with reduced glycoursodeoxycholic acid (GUDCA) in osteoarthritis. Suppressing farnesoid X receptor (FXR)-the receptor of GUDCA-alleviated osteoarthritis through intestine-secreted glucagon-like peptide 1 (GLP-1) in mice. GLP-1 receptor blockade attenuated these effects, whereas GLP-1 receptor activation mitigated osteoarthritis. Osteoarthritis patients exhibited a lower relative abundance of
2. Large-Scale Proteomics Improve Risk Prediction for Type 2 Diabetes.
In UK Biobank, adding a 15-protein panel (Olink Explore) to CDRS improved discrimination (ΔC-index 0.029) with substantial net reclassification. A simpler 6-protein inflammation panel improved discrimination (ΔC-index 0.016) and replicated in ESTHER (ΔC-index 0.014), supporting translational potential.
Impact: Demonstrates that targeted proteomics can meaningfully enhance established clinical risk scores, advancing precision prevention strategies for type 2 diabetes.
Clinical Implications: Proteomic panels could refine risk stratification beyond clinical factors, guiding earlier interventions and trial enrichment; further external validation and cost-effectiveness analyses are needed.
Key Findings
- A 15-protein Olink Explore panel improved CDRS discrimination by 0.029 with 23% net reclassification.
- A 6-protein inflammation panel improved CDRS by 0.016 and externally validated in ESTHER (ΔC-index 0.014).
- Both proteomic models outperformed CDRS alone, supporting biomarker-enhanced risk prediction.
Methodological Strengths
- Large derivation cohort with internal validation and independent external validation.
- Use of high-throughput proteomics (2,085 proteins) and parsimonious panels for translation.
Limitations
- External validation performed only for the 6-protein model; the 15-protein model needs replication.
- Clinical utility and cost-effectiveness were not directly assessed.
Future Directions: Prospective impact studies, multi-ancestry validation, integration with genomics and metabolomics, and implementation studies assessing clinical utility and cost-effectiveness.
OBJECTIVE: This study evaluated the incremental predictive value of proteomic biomarkers in assessing 10-year type 2 diabetes risk when added to the clinical Cambridge Diabetes Risk Score (CDRS). RESEARCH DESIGN AND METHODS: Data from 21,898 UK Biobank participants were used for model derivation and internal validation, and 4,454 Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung (ESTHER) cohort (Germany) participants were used for external validation. Proteomic profiling included the Olink Explore (2,085 proteins) and Olink Target 96 Inflammation panel (73 proteins). RESULTS: Adding 15 proteins from Olink Explore or 6 proteins from the Olink Inflammation panel improved the C-index of the CDRS by 0.029 or 0.016 in internal validation with net reclassification of 23.0% and 29.0%, respectively. External validation was only conducted for the six-protein-extended model, and the C-index improved by 0.014. CONCLUSIONS: The Olink Explore-based 15-protein model enhanced the CDRS model performance most, and this promising prediction model should be externally validated. Our successful external validation of the Olink Inflammation panel-based six-protein model shows that this is a promising endeavor.
3. Testosterone Effects on Short-term Physical, Hormonal, and Neurodevelopmental Outcomes (TESTO) in Infants With 47,XXY.
Testosterone given during minipuberty to infants with 47,XXY increased lean mass and reduced fat mass z-scores over 12 weeks and strongly suppressed gonadotropins/inhibin B, but did not improve short-term motor, cognitive, or language outcomes. Routine early testosterone treatment is not supported.
Impact: A high-quality pediatric RCT that directly informs practice by demonstrating lack of short-term neurodevelopmental benefit despite anabolic effects and HPG-axis suppression.
Clinical Implications: Do not routinely prescribe testosterone during minipuberty for infants with 47,XXY; monitor growth and endocrine axes, and prioritize long-term outcome studies before adopting treatment.
Key Findings
- Lean mass increased and fat mass z-scores decreased with testosterone versus placebo over 12 weeks.
- Gonadotropins and inhibin B were significantly suppressed by testosterone (P < .001).
- No improvement in short-term motor, cognitive, or language outcomes was observed.
Methodological Strengths
- Double-blind randomized controlled design with prespecified primary outcomes.
- Objective body composition measures and comprehensive hormonal assessments.
Limitations
- Short follow-up (12 weeks) limits assessment of developmental trajectories.
- Single dosing regimen; dose–response and timing effects remain unknown.
Future Directions: Long-term follow-up through childhood for neurodevelopment, metabolic health, and testicular function; evaluate alternative dosing/timing strategies and benefit–risk balance.
CONTEXT: 47,XXY/Klinefelter syndrome (XXY) is associated with impaired testicular function and differences in physical growth, metabolism, and neurodevelopment. Clinical features of XXY may be influenced by testosterone during the minipuberty period of infancy. OBJECTIVE: We tested the hypothesis that exogenous testosterone treatment positively affects short-term physical, hormonal, and neurodevelopmental outcomes in infants with XXY. DESIGN: Double-blind randomized controlled trial, 2017-2021. SETTING: US tertiary care pediatric hospital. PATIENTS: Infants 30 to 90 days of age with prenatally identified, nonmosaic 47,XXY (n = 71). INTERVENTION: Testosterone cypionate 25 mg IM injections every 4 weeks for 3 doses. MAIN OUTCOME MEASURES: The a priori primary outcomes were change in percent fat mass z-scores and change in the total composite percentile on Alberta Infant Motor Scales assessment from baseline to 12 weeks. RESULTS: The between-group difference in change in percent fat mass z-scores was -0.57 (95% CI, -1.1 to -0.06; P = .03), secondary to greater increases in lean mass in the testosterone-treated group (1.5 ± 0.4 kg vs 1.2 ± 0.4; P = .001). Testosterone suppressed gonadotropins and inhibin B (P < .001 for all). In contrast, there were no significant group differences in short-term motor, cognitive, or language outcomes (P > .15 for all). CONCLUSIONS: In this double-blind randomized controlled trial in infants with XXY, testosterone injections resulted in physical effects attributable to systemic androgen exposure; however, this dose suppressed the hypothalamic-pituitary-gonadal axis. Neurodevelopment outcomes were not impacted by treatment. These results do not support routine testosterone treatment in infants with XXY; however, long-term follow-up on physical health, neurodevelopment, and testicular function is needed.